Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
Intravenous continuous infusion of betalactam (CIBL) antibiotic and high dose extended interval (HDEI) aminoglycoside therapy theoretically maximize bacterial killing in treatment of Pseudomonas aeruginosa (PsA) in pulmonary exacerbations of cystic fibrosis (CF). We present the case of a 3-month-old female infant with CF who failed outpatient eradication of PsA with subsequent eradication using intravenous CIBL antibiotic and HDEI aminoglycoside therapy. This antibiotic combination should be considered in order to optimize pharmacodynamics for PsA eradication in CF patients before development of chronic colonization.
Hayes
Don
D
Departments of Pediatrics and Internal Medicine, University of Kentucky College of Medicine, J410 Kentucky Clinic, 740 South Limestone Street, Lexington, Kentucky 40536, USA. don.hayes@uky.edu
Kanga
Jamshed F
JF
Anstead
Michael I
MI
Kuhn
Robert J
RJ
D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019540:Area Under Curve; D003550:Cystic Fibrosis / Q000382:microbiology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007297:Inpatients; D010045:Outpatients; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D017211:Treatment Failure; D016896:Treatment Outcome; D047090:beta-Lactams / Q000008:administration & dosage / Q000627:therapeutic use*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D047090:beta-Lactams